Which drug first? new study aims to optimize breast cancer treatment sequence
NCT ID NCT07162259
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at the best order to give two powerful antibody-drug conjugates (ADCs) — T-DXd and SG — to people with a common type of advanced breast cancer (HR+/HER2-). After standard hormone therapy stops working, doctors are unsure which drug to use first. The study will enroll 40 adults and track how long each sequence controls the cancer, as well as side effects. The goal is to find a smarter, personalized treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG)
What this could lead to
If successful, this could help doctors choose the best sequence of these two drugs to extend life and improve quality of life for patients with advanced breast cancer.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the best sequence may not be clearly better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an International Medical Center Hospital
Xi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••